PBAC's latest decision on Nadroparin calcium: Recommended (2016). Considered for Prophylaxis against deep vein thrombosis (DVT) associated with general or orthopaedic surgery, treatment of DVT, and prevention of clotting during haemodialysis.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2015
Submissions
2
2015 → 2016
Eligible population
Patients requiring prophylaxis against DVT associated with general or orthopaedic surgery, treatment of DVT, or prevention of clotting during haemodialysis.
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
enoxaparin
Economic model
Cost-minimisation
ICER note
Minor submission; cost-minimisation basis; no economic model evaluation in scope.